Since our founding in 2004, Vaxart has pursued a vision of developing vaccines that can be administered by tablet rather than by injection.
In the rapidly growing $25 billion global vaccines market, vaccines that are administered by room temperature–stable tablet can be a game changer. They could dramatically increase the effectiveness of large annual vaccination campaigns, such as for seasonal influenza, and offer an optimal approach to respond to newly emerging pathogens, such as Ebola, in regions with limited infrastructure.
Vaxart tablet vaccines currently in development for seasonal and pandemic influenza and Ebola feature:
Vaxart is a privately held, clinical-stage company. Our proprietary oral vaccine delivery platform is suitable to deliver any recombinant vaccine, positioning Vaxart to introduce oral versions of multiple blockbuster vaccines.
Our platform technology allows rapid development to address emerging threats or fast-moving outbreaks. We can develop a vaccine in a matter of weeks and deliver it into virtually any conditions, no matter how limited the infrastructure.